Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. - Wikidata - wikimedia - TriplyDB

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

http://www.wikidata.org/entity/Q34070129

about

Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts Future directions for monitoring treatment response in colorectal cancer Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis Surgery for colorectal liver metastases: The evolution of determining prognosis Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status Selection for hepatic resection of colorectal liver metastases: expert consensus statement Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal.Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation.High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.The role of peri-operative treatment in resectable liver metastases of colorectal cancer.Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?Complete clinical response of liver metastasis after chemotherapy: To resect or not?Update on the role of imaging in management of metastatic colorectal cancer Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Recent advances in the curative treatment of colorectal liver metastases Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.Computerized PET/CT image analysis in the evaluation of tumour response to therapy.Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy?

P2860

Q26774687-969FCA69-D5DE-43F8-9010-9BB1F42C44ED Q26797292-075F4A0E-1C98-4A19-A38E-FA1A7381A86E Q26863654-17FC36CE-1A80-4AAA-BFE6-82AC48324AB7 Q27008428-B52DC8CF-D939-451B-8D08-AD855890DABB Q27009240-3DD068DA-140B-4EEC-93F8-EBBAD6C13538 Q27014926-EC2E34A2-F744-41DE-AF39-FAFB4D5D6836 Q27026936-B3EF7356-5B90-44F4-94BC-B508D781BF19 Q27694490-C3B92AE3-E1F1-4D2D-A4B6-61F71CF36C4E Q27852191-1D3881E7-CFCB-42B8-8F13-BF7EABA9DDEA Q28066171-80D3FC5A-5683-4221-9D8F-76E4484A5028 Q28067562-21846B92-CEE1-4A89-A739-CABB47114A31 Q28075777-72184321-EDA3-44F8-A9AA-C3238D1C0ADF Q30415026-38DDEB8F-9A3C-4426-AB74-878E3D71C980 Q31131324-3FB23396-4C91-4572-AB45-3BBE632A9543 Q33770680-69C7E1A9-6182-47F1-ADCE-C99EB5A12EBD Q33889809-23E4B025-1A01-47D0-ACFD-715DF36D5DCD Q33906344-DE817C3C-13BE-43D0-A854-DAD3FAD8165A Q34373547-99BB69BA-58D7-47FF-80DC-72FA6592F4B7 Q34743458-731FA16A-B059-4BBB-9F84-14DD113F2BB9 Q34745831-8CAD21E2-2DC4-4C83-837E-CAFDE5837A19 Q35054390-E901965D-7AF2-4244-A6E4-8BDF35D89730 Q35076305-6E8E39E4-E2B6-4D83-8BAD-20AC9BBD237F Q35082383-42DEBF3F-BCFB-4B8B-B431-758514F08D2A Q35172858-BB837B55-1174-4D34-8FF9-92EEEC601485 Q35285305-8F3A3A85-C899-4484-9FA1-DED88710F814 Q35622772-7772C67C-4DB8-4CC8-9B85-3796C7DB7C0A Q35670736-59176DED-909E-4542-B775-8717DB2841E5 Q35709696-085C42F6-2209-418D-B8B7-7D4917051B7D Q35767565-68BA09F4-4E3C-497D-B75A-B389AE0784BE Q35835193-FA9D8D9D-1EA4-4B60-9164-97F11DB6A3B1 Q35869753-BEBABDF8-85F0-4F86-8BC4-681E585CB492 Q36084851-E28D6EC8-40AA-4955-9883-8C74A7541E93 Q36145455-2A75DF4D-D3D2-4D71-ACFC-2D3548FFEE11 Q36286704-B40C41B2-C579-4BA4-8C94-F5AF9A272BF7 Q36295403-58485A9D-6F18-4616-A427-708CED960BF8 Q36343047-F5E627B0-DCDC-4FFA-B6F2-E064282BB530 Q36349575-8FC02B5B-FE8E-4520-9BD1-AE6A13E25F0B Q36457189-AABF8C0D-ADA0-49BF-8D84-B2891718E7F8 Q36545344-CC4C29A5-F1F5-40AC-8180-B1E12F3E1029 Q36719842-83EC8970-8343-42A7-A631-F0C951DD52B0

P2860

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

http://www.wikidata.org/entity/Q34070129

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Association of computed tomogr ...... r colorectal liver metastases.

@ast

Association of computed tomogr ...... r colorectal liver metastases.

@en

Association of computed tomogr ...... r colorectal liver metastases.

@nl

type

label

Association of computed tomogr ...... r colorectal liver metastases.

@ast

Association of computed tomogr ...... r colorectal liver metastases.

@en

Association of computed tomogr ...... r colorectal liver metastases.

@nl

prefLabel

Association of computed tomogr ...... r colorectal liver metastases.

@ast

Association of computed tomogr ...... r colorectal liver metastases.

@en

Association of computed tomogr ...... r colorectal liver metastases.

@nl

P1433

Q34070129-E88F4423-E025-4AA0-A977-0FFA62802733

P1476

Q34070129-E92A6069-4E0B-423A-83A9-D3CAE8A39274

P2093

Q34070129-137585F4-1FA7-449C-85DE-6E00882531A3

Q34070129-4946C4BB-5599-4983-BBB0-B47A92C592FD

Q34070129-515F4F77-C52C-4B20-A2D0-6B33E93C91EC

Q34070129-8E152F54-EA20-44B4-9249-44AB054CC6DA

Q34070129-93E42974-24C6-49FE-B3FC-FBAED9C211E3

Q34070129-9C0FE283-35C6-47B2-8404-0CC410B783D7

Q34070129-9FD89E2C-B571-48DD-8D64-66CB2BAB671A

Q34070129-A041A15E-4B49-42CE-920F-186825CE6A4A

Q34070129-ADAF4F1C-7A4B-4FFF-8C94-35F4A75FB4B6

Q34070129-CC4E4BF9-9697-460B-BBF1-8363128E368B

P2860

Q34070129-128A6FBD-462E-446C-A49A-B5D8D476277E

Q34070129-15DB9178-E110-430F-B417-E08551D7ECDE

Q34070129-38A5982E-245B-48E5-8E6D-FBCCD4D8BF59

Q34070129-41B2AFB6-99F0-4109-8A04-E7703B7BE0D0

Q34070129-5EE714D1-A08B-444A-9E68-DA7D3311008C

Q34070129-63D71F2B-737D-4808-B0AB-F462E0FE4705

Q34070129-8FED1DC8-FF21-46A5-900E-1A6B53ED4FC0

Q34070129-92260EB4-819E-4D6B-A0B3-4CB1745E4CB3

Q34070129-AC9E66F8-B1AA-4582-A00E-CCF38D363214

Q34070129-B925F623-E5B0-4ADC-80CA-F83E436CF1A0

P304

Q34070129-A33DE350-79F5-4269-8782-CE7BB42D6735

P31

Q34070129-B85A2AFC-3173-4C4A-A3DC-17517F163903

P356

Q34070129-CF4DA945-83C4-4E77-AECD-DA00C02762B0

P407

Q34070129-857BF7C9-EFF3-4168-9224-ADD2C68C3F0F

P433

Q34070129-76A53C53-F6F4-42AE-86BB-7F554E58764E

P478

Q34070129-C669F51D-B11B-45BA-91D0-61FAB41EE598

P50

Q34070129-0A512CA4-27C4-4379-B50C-4D6A6E34F56F

P577

Q34070129-A2137872-397C-401A-A9FF-F437690D8F13

P698

Q34070129-44472F68-A8AF-406B-972B-17920F05232B

P921

Q34070129-21C1932E-8B3C-475A-B7CB-378CFBEBAEF8

Q34070129-F7EB1E2C-6AEC-40E3-8531-A0CED0676BD2

P932

Q34070129-3F4D1986-7E07-48E0-A271-1F2059633103

P356

P1433

Journal of the American Medical Association

P1476

Association of computed tomogr ...... r colorectal liver metastases.

@en

P2093

Chusilp Charnsangavej

http://www.w3.org/2001/XMLSchema#string

Dipen M Maru

http://www.w3.org/2001/XMLSchema#string

Eddie K Abdalla

http://www.w3.org/2001/XMLSchema#string

Evelyne M Loyer

http://www.w3.org/2001/XMLSchema#string

Harmeet Kaur

http://www.w3.org/2001/XMLSchema#string

Martin Palavecino

http://www.w3.org/2001/XMLSchema#string

Piyaporn Boonsirikamchai

http://www.w3.org/2001/XMLSchema#string

Scott Kopetz

http://www.w3.org/2001/XMLSchema#string

Steven A Curley

http://www.w3.org/2001/XMLSchema#string

Yun Shin Chun

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Imaging of angiogenesis: clinical techniques and novel imaging methods.

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.

P304

2338-2344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2009.1755

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

302

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Nicolas Vauthey

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19952320

http://www.w3.org/2001/XMLSchema#string

P921

P932

4139149

http://www.w3.org/2001/XMLSchema#string